

## Osprey Medical and AKI highlighted at largest international cardiovascular conference TCT 2017

### Highlights:

- Osprey Medical showcased at the 29<sup>th</sup> Transcatheter Cardiovascular Therapeutics (TCT) conference with two scientific sessions focused on awareness and prevention of Acute Kidney Injury (AKI)
- Osprey Medical features its next generation Be Kind to Kidneys™ Program

**November 3, 2017 – Melbourne, Australia and Minnesota, United States** – Osprey Medical (ASX:OSP) is pleased to share its high exposure presence and featured clinical experience with the DyeVert™ Plus System during the 29<sup>th</sup> annual TCT Conference held this past week in Denver, Colorado.

Presented at TCT's CI-AKI: Preventive Measures That Work lunch symposium, three of the talks focused on the importance of contrast reduction as a component to reducing the risk of AKI in the cardiac catheterization lab. The key presentations included *"The current state of CI-AKI in the cath lab"* (Dr. Roxanne Mehran), *"Effective methods for reducing contrast dosage to patients: The DyeVert Plus System"* (Dr. Anand Prasad, M.D), and *"Practical application for incorporating hydration and dye-saving protocol for patients at high risk for AKI"* (Gautum Kumar M.D.).

Additionally, the CME (continuing medical education) accredited Hot Topic Session, Focus on Chronic Kidney Disease and Contrast Nephropathy, provided a comprehensive overview and prevention of AKI and managing special scenarios with patients at risk for AKI.

Osprey Medical featured its new tradeshow booth with its *Be Kind to Kidney* program highlighted to create awareness and education around the clinical society guidelines to Screen, Hydrate, and Reduce Contrast when treating high-risk patients.

Osprey Medical's President and CEO, Mike McCormick, said: "This was a very successful TCT for Osprey Medical and provided us with high exposure to the physicians who are ultimately the end users of our one of a kind technology. We had very high booth traffic throughout the conference, particularly following the scientific presentations. Pleasingly, we are seeing growing awareness of the CI-AKI problem and physicians who visited our booth were looking for practical solutions to comply with clinical guidelines in treating high-risk patients in the cath lab."

<http://ospreymed.com/be-kind-to-kidneys/>

### Contact details:

#### Media

Amanda Loh  
Buchan Consulting  
T: (613) 8866 1210  
[aloh@buchanwe.com.au](mailto:aloh@buchanwe.com.au)

#### Investors

Rebecca Wilson  
Buchan Consulting  
M: (61) 417 382 391  
[rwilson@buchanwe.co.au](mailto:rwilson@buchanwe.co.au)

#### Company

Doug Schoenberg  
VP of Marketing  
T: (952) 955 8230  
[dschoenberg@ospreymed.com](mailto:dschoenberg@ospreymed.com)

### About Osprey

Osprey Medical is focused on protecting patients from the harmful effects of X-ray dye (contrast) used during commonly performed angiographic imaging procedures. The Company's core technologies originated from research conducted by Dr David Kaye at Melbourne's Baker IDI Heart and Diabetes Institute. Its proprietary dye reduction and monitoring technologies are designed to help physicians minimize dye usage. The Company's DyeVert™ System is a next-generation product that reduces contrast while maintaining image quality in a self-adjusting easy-to-use design. Osprey Medical's Board and

Management are comprised of experienced and successful personnel with established track records covering medical device development, regulatory approvals, sales and marketing, and mergers-acquisitions.

### **Forward-Looking Statements**

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our products including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position. Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Osprey does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Osprey may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.